硫丙麦角林在治疗帕金森病中的疗效与安全性

目的 观察长期用硫丙麦角林和复方左旋多巴治疗帕金森病(PD)的疗效与不良反应。方法 对我院PD专病门诊中应用本药长期治疗观察的42例作回顾性分析。结果36/42例(86％)用该药有效,维持剂量250～750μg/d。35.7％有轻微不良反应,多在2周后好转,便秘常持续存在。结论 用硫丙麦角林有效率86％,耐受性较好。与安坦、金刚烷胺、左旋多巴合用能增加疗效。

硫丙麦角林对帕金森病的疗效观察

目的:观察硫丙麦角林并用复方左旋多巴治疗帕金森病(PD)的疗效与副作用.方法:回顾性分析我院PD专病门诊中应用本药长期治疗观察的31例(2例单用硫丙麦角林).结果:26/31例(83.4%)用该药有效,维持剂量150μg～500μg/d.34%有轻微不良反应,便秘常见.结论:用硫丙麦角林有效率83%,耐受性较好.与安坦、金刚烷胺、左旋多巴合用能增加疗效.本荆为临床可选用的DA受体激动剂之一.

培高利特(硫丙麦角林)在帕金森病中的应用与心脏瓣膜反流有关

Objective: To determine if pergolide injures heart valves, by comparing echocardiographic findings in pergolide treated patients with those of a historical control group. Methods: Letters were sent to all patients in the authors’ practice believed to be taking pergolide, and those responders who wished to continue it were urged to undergo echocardiography. Echocardiograms were obtained on 46 patients, and scores for valvular regurgitation were compared with those from an age matched control group derived from the Framingham Study. The composite valve regurgitation score was modeled as a linear function of total milligrams lifetime use of pergolide, controlling for age. Results: Eightynine percent of pergolide treated patients had some degree of valvular insufficiency. For each of the three valves for which there are control data, we found an approximately 2 to 3 fold increased risk of abnormal valves in the pergolide patients (odds ratio ≈ 3) and an estimated 14 fold increased risk of concerning tricuspid regurgitation (OR = 18.4). The composite valve score (the sum of valve scores for each of the four valves) was a function of lifetime pergolide use. Conclusion: Pergolide may injure cardiac valves, resulting most commonly in tricuspid regurgitation.

硫丙麦角林治疗帕金森病23例临床观察

目的：观察硫丙麦角林并用左旋多巴治疗帕金森病（ＰＤ）的疗效与副作用。方法：回顾性分析我院ＰＤ专病门诊中应用本药长期观察的２３例（２例单用硫丙麦角林）。结果：１９／２３例（８３％）用该药有效，维持剂量１５０μｇ～５００μｇ／日。３５％有轻微不良反应，便秘常见。结论：用硫丙麦角林有效率８３％（１７／２１例与左旋多巴类并用），耐受性较好。可与安坦、金刚烷胺、左旋多巴合用并能增加疗效，为临床可选用的ＤＡ受体激动剂之一。

帕金森综合征药物治疗的近代观点(三)

溴隐亭(Br)、Br并用左旋多巴(LD)、LD三个治疗组对比 Nakanish等1988,1989、1990先后三次报告日本181个医疗机构治疗帕金森病(PD)一、二、三年的结果。Ⅰ组单用Br286例,ⅡA组并用Br及LD216例,ⅡB组单用LD200例。

帕金森病药物治疗中的若干问题

帕金森病（Parkinson＇s disease，PD）的药物治疗一直是临床研究和实践中的关注重点。近年来，伴随着PD治疗指南的陆续制定，PD的药物治疗日趋规范和合理。然而不可否认的是，在药物治疗过程中，仍有一些棘手的问题尚未完全解决，一些新问题不断地出现，从左旋多巴诱发的异动症到近期硫丙麦角林引起的心脏瓣膜病变，事实一次次地告诉我们：伴随新型药物的问世和使用，以及我们对某些症状和体征的渐进认识，PD的药物治疗仍然是一个在宏观的总体原则下具有动态性、自我更新性特点，深刻体现与时俱进、不断发展理念的临床课题。